VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 11, 2006) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that the results of the Phase IIa study of IPL512,602 in patients with mild-moderate persistent asthma will be presented at the 2006 American Thoracic Society (ATS) International Conference being held May 19-24, 2006 in San Diego, California. The title of the presentation is: The Effect of IPL512,602 in Patients with Mild-Moderate Persistent Asthma (NEAT Study).
